Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Pliant Therapeutics (PLRX) over the last 5 years, with Q3 2025 value amounting to 3222.82%.

  • Pliant Therapeutics' EBITDA Margin changed N/A to 3222.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 7276.64%, marking a year-over-year change of. This contributed to the annual value of 10065.38% for FY2023, which is 87739200.0% down from last year.
  • Pliant Therapeutics' EBITDA Margin amounted to 3222.82% in Q3 2025.
  • Over the past 5 years, Pliant Therapeutics' EBITDA Margin peaked at 7049.81% during Q1 2025, and registered a low of 16976.61% during Q2 2023.
  • Its 4-year average for EBITDA Margin is 1243.12%, with a median of 1276.86% in 2021.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 6784400bps in 2022, then tumbled by -163782000bps in 2023.
  • Quarter analysis of 4 years shows Pliant Therapeutics' EBITDA Margin stood at 1235.22% in 2021, then crashed by -42bps to 1758.98% in 2022, then tumbled by -865bps to 16976.61% in 2023, then surged by 119bps to 3222.82% in 2025.
  • Its EBITDA Margin was 3222.82% in Q3 2025, compared to 5372.06% in Q2 2025 and 7049.81% in Q1 2025.